TY - JOUR
T1 - Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma
T2 - Efficacy of low doses
AU - Cetto, G. L.
AU - Franceschi, T.
AU - Turrina, G.
AU - Chiaron-Sileni, V.
AU - Capelli, M. C.
AU - Bellini, A.
AU - Paccagnella, A.
AU - Bassetto, M. A.
AU - Molino, A. M.
AU - De Sandre, G.
PY - 1988
Y1 - 1988
N2 - Twenty-six patients with metastatic renal cell carcinoma (RCC) were treated in a phase I-II trial with recombinant interferon alpha-2b (α-IFN) and vinblastine (VBL) in combination. Patients received IFN at a starting dose of 3 x 106 IU/m2 subcutaneously three times a week and VBL 0.1 mg/kg intravenously every 3 weeks, with dose modification for toxicity. All patients were evaluable for toxicity; 18 patients were evaluable for efficacy. An objective response rate of 44% was observed (eight of 18 patients, with one complete response and seven partial responses). The median duration of response was 5 months. The actuarial survival of responding patients was significantly longer than that of nonresponding patients. In general, the toxicity was tolerable; the subjective toxicity and fever were similar to that reported for the same doses of IFN alone. Only a mild neurotoxicity, usually mixed polyneuropathy, occurred with increased frequency. Alpha-IFN and VBL administered at low doses in combination demonstrated the highest response rate so far reported in RCC without significant toxicity.
AB - Twenty-six patients with metastatic renal cell carcinoma (RCC) were treated in a phase I-II trial with recombinant interferon alpha-2b (α-IFN) and vinblastine (VBL) in combination. Patients received IFN at a starting dose of 3 x 106 IU/m2 subcutaneously three times a week and VBL 0.1 mg/kg intravenously every 3 weeks, with dose modification for toxicity. All patients were evaluable for toxicity; 18 patients were evaluable for efficacy. An objective response rate of 44% was observed (eight of 18 patients, with one complete response and seven partial responses). The median duration of response was 5 months. The actuarial survival of responding patients was significantly longer than that of nonresponding patients. In general, the toxicity was tolerable; the subjective toxicity and fever were similar to that reported for the same doses of IFN alone. Only a mild neurotoxicity, usually mixed polyneuropathy, occurred with increased frequency. Alpha-IFN and VBL administered at low doses in combination demonstrated the highest response rate so far reported in RCC without significant toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0023711151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023711151&partnerID=8YFLogxK
M3 - Article
C2 - 3055162
AN - SCOPUS:0023711151
VL - 4
SP - 184
EP - 190
JO - Seminars in Surgical Oncology
JF - Seminars in Surgical Oncology
SN - 8756-0437
IS - 3
ER -